PerspectiveAn update on current practices in the management of ocular toxoplasmosis1, 2☆,
Section snippets
Questionnaire
Only those recipients who treat patients with ocular toxoplasmosis were asked to complete the questionnaire. These recipients were asked whether they treated all cases of typical ocular toxoplasmosis regardless of ocular findings. A case of typical ocular toxoplasmosis was defined as an immunocompetent adult man or nonpregnant woman with a focus of recurrent toxoplasmic retinochoroiditis at the border of a preexisting scar that is not involving the fovea or optic disk, but could affect those
Respondents
The American Uveitis Society includes clinicians and laboratory scientists with a special interest in ocular inflammation. For membership in the American Uveitis Society, physicians must have had fellowship training in uveitis or have been in practice for at least 3 years after residency training, with 25% of their patient-care time spent in the treatment of patients with intraocular inflammation; alternatively, they must be engaged in full-time laboratory research dealing with inflammatory
Survey results
Some respondents did not answer every question. The proportion of respondents providing a given answer was calculated by dividing the number of respondents giving that answer by the number of respondents answering the corresponding question. Information cited from the 1991 survey was taken either from the publication describing its results1 or from data summaries that had been archived in the Jules Stein Eye Institute Clinical Research Center.
To justify the use of current results as a new
Discussion
T. gondii infection is worldwide in distribution and toxoplasmic retinochoroiditis is the most common form of posterior uveitis in otherwise healthy individuals, both in tertiary referral and in community-based practices of comprehensive ophthalmology.26 Ocular toxoplasmosis can lead to severe vision loss in some patients. Appropriate treatment is therefore a subject of great importance.
This survey was not intended as a scientific sampling of all clinicians who evaluate and treat patients with
Acknowledgements
Bette L. Okeya, Pharm. D. of the Drug Information Service (UCLA Medical Center, Los Angeles, CA) provided information about the commercial availability of antiparasitic agents. Robert E. Engstrom, Jr., MD (Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles, CA), Douglas A. Jabs, MD, MBA (Wilmer Ophthalmologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD), and Robert B. Nussenblatt, MD (National Eye Institute, National Institutes of Health, Bethesda, MD),
References (41)
- et al.
Current practices in the management of ocular toxoplasmosis
Am J Ophthalmol
(1991) - et al.
Therapy for ocular toxoplasmosis
Am J Ophthalmol
(1993) - et al.
Atovaquone for the treatment of Toxoplasma retinochoroiditis in immunocompetent patients
Ophthalmology
(1999) - et al.
Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis
Ophthalmology
(1992) - et al.
Atypical, severe toxoplasmic retinochoroiditis in elderly patients
Ophthalmology
(1997) - et al.
Ocular toxoplasmosis after the fifth decade
Am J Ophthalmol
(2002) - et al.
Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome
Am J Ophthalmol
(1988) - et al.
Ocular toxoplasmosis in human immunodeficiency virus-infected patients
Am J Ophthalmol
(1992) - et al.
Eye manifestations of congenital toxoplasmosis
Am J Ophthalmol
(1996) - et al.
Recurrent ocular disease in post-natally acquired toxoplasmosis
Am J Ophthalmol
(1999)
Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis
Am J Ophthalmol
Reconsidering the pathogenesis of ocular toxoplasmosis
Am J Ophthalmol
Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection
Am J Ophthalmol
A follow-up study of Toxoplasma gondii infection in southern Brazil
Am J Ophthalmol
Standardization of vitreal inflammatory activity in intermediate and posterior uveitis
Ophthalmology
Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group
Am J Ophthalmol
Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine
Ophthalmology
Clindamycin in the treatment of toxoplasmic retinochoroiditis
Am J Ophthalmol
Fulminant ocular toxoplasmosis
Am J Ophthalmol
Azithromycin for ocular toxoplasmosis
Br J Ophthalmol
Cited by (157)
A new perspective in the treatment follow-up of toxoplasma retinochoroiditis: Infiltrate thickness measurement
2023, Photodiagnosis and Photodynamic TherapyPrimary ocular toxoplasmosis secondary to venison consumption
2023, American Journal of Ophthalmology Case ReportsToxoplasmosis
2023, Manson's Tropical Diseases, Fourth EditionLincosamide Antibiotics
2022, Comprehensive PharmacologyOcular toxoplasmosis in immunocompetent adults: current cost-effectiveness of four treatment regimens in Colombia
2021, HeliyonCitation Excerpt :As shown in Table 5, when compared with the other treatment alternatives, TMP-SMX showed the best cost-effectiveness performance, with a mean cost-effectiveness that ranged from seven to 17 percentage points above the other options, as well as the highest value for net monetary benefits. Concerning second-line treatments that were used in the event of therapeutic failure or severe adverse effects, regardless of changes made in the first-line treatments, intravitreal clindamycin demonstrated the highest effectiveness (87%) among the four regimens, with a cost of 473 USD; thus, it is highly effective as rescue therapy, consistent with previous reports [10, 12]. A Monte Carlo simulation was conducted to evaluate the model consistency and the degree of uncertainty involved, including 10,000 iterations.
Classification Criteria for Toxoplasmic Retinitis
2021, American Journal of Ophthalmology
- ☆
This work was supported in part by Research to Prevent Blindness, Inc., New York, NY, the Skirball Foundation, Los Angeles, CA, and the David May II Endowed Professorship (G.N.H.). Dr. Holland is recipient of a Research to Prevent Blindness, Inc., Lew R. Wassermann Merit Award.
- 1
InternetAdvance publication at ajo.com April 12, 2002.
- 2
Additional information is available online at ajo.com.